Arcus Biosciences, Inc. (NYSE:RCUS) CFO Sells $53,910.00 in Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CFO Robert C. Goeltz II sold 3,594 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the completion of the transaction, the chief financial officer now directly owns 60,138 shares in the company, valued at approximately $902,070. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Arcus Biosciences Trading Down 0.5 %

Shares of RCUS stock opened at $15.06 on Monday. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The firm has a market cap of $1.38 billion, a P/E ratio of -4.78 and a beta of 0.87. The company has a 50 day moving average of $15.91 and a 200-day moving average of $16.01. Arcus Biosciences, Inc. has a 12-month low of $13.52 and a 12-month high of $20.31.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Wednesday, November 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.06. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The firm had revenue of $48.00 million for the quarter, compared to analyst estimates of $38.95 million. The business’s revenue was up 50.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.94) earnings per share. Sell-side analysts anticipate that Arcus Biosciences, Inc. will post -3.2 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $20.00 price target on shares of Arcus Biosciences in a research note on Wednesday, November 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. Wells Fargo & Company initiated coverage on shares of Arcus Biosciences in a research report on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 price target on the stock. Barclays lifted their target price on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. Finally, Wedbush restated an “outperform” rating and set a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $34.00.

Institutional Investors Weigh In On Arcus Biosciences

Several institutional investors have recently added to or reduced their stakes in RCUS. Point72 Hong Kong Ltd purchased a new position in shares of Arcus Biosciences in the third quarter worth about $47,000. Point72 DIFC Ltd purchased a new position in Arcus Biosciences in the 2nd quarter valued at approximately $83,000. Quest Partners LLC raised its holdings in Arcus Biosciences by 40,904.3% during the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after acquiring an additional 9,408 shares during the period. Intech Investment Management LLC purchased a new stake in shares of Arcus Biosciences during the third quarter worth $244,000. Finally, Martingale Asset Management L P bought a new position in shares of Arcus Biosciences in the third quarter worth $251,000. 92.89% of the stock is owned by hedge funds and other institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.